Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOakley Regulatory News (OCI)

Share Price Information for Oakley (OCI)

Share Price is delayed by 15 minutes
Get Live Data
518.00    -2.00 (-0.38%)
Bid:
516.00
Ask:
520.00
Spread: 4.00 (0.775%)
Market Cap: £857.11m
OCI Live PriceLast checked at - London Stock Exchange

Intraday Oakley Share Chart

Trading Update

9 Feb 2015 07:00

RNS Number : 3441E
Oakley Capital Investments Limited
09 February 2015
Β 

09 February 2015

Β 

Oakley Capital Investments Limited ("OCIL" or the "Company")

Β 

Trading Update for the 12 months ended 31 December 2014

Β 

Β· NAV per share (unaudited) expected to be in the range of Β£1.99 - Β£2.01

Β· Four acquisitions in the period with a total enterprise value of Β£227 million

Β· Successful exits, including a post reporting period disposal, achieved a gross money multiple of 2.6x and an IRR of 58%, returning Β£73 million to the Company

Β· Final close of Fund II with total commitments of €524 million

Β 

Oakley Capital Investments Limited (AIM: OCL), the AIM-listed company established to provide investors with access to the investment strategy being pursued by Oakley Capital Private Equity L.P. ("Fund I") and its successor fund, Oakley Capital Private Equity II ("Fund II") (together the "Funds"), today announces a trading update for the 12 months ended 31 December 2014.

Β 

The Company, through its investment in Fund I, has an indirect interest in each of Fund I's portfolio companies representing 65.5% of Fund I's total commitments; and through its investment in Fund II, an indirect interest in each of Fund II's portfolio companies representing 38.1% of Fund II's total commitments.

Β 

Oakley Capital Limited, OCIL's investment adviser, estimates that the Company's net asset value, which is subject to the completion of the 31 December 2014 audit of the Funds, and the Company, will be in the range of Β£255 million to Β£257 million, equating to a net asset value per share of between Β£1.99 to Β£2.01 (31 December 2013: Β£2.00). The OCIL net asset value is made up of cash, the investments in the Funds, short-term bridging finance for the Funds and loans provided to a number of the portfolio companies.

Β 

The Board has authorised a share buy-back programme of up to 7 million ordinary shares in the Company at prices below the estimated net asset value per share.

Β 

Β 

Key HighlightsΒ 

Β· Fund II closed in December 2014 with total commitments of €524 million, including €200 million from the Company and over 10% of commitments from management teams Oakley Capital Private Equity has previously backed.Β 

Β· Fund II's rapid capital deployment, including acquisitions of:

- Majority stakes in North Technology Group LLC ("North Sails") and North Sails Europe LLC ("NSE") and North Sail's subsequent acquisition of Tomasoni Topsail SpA. Collectively these acquisitions will enable the leading marine technology group, North Sails, to operate on a global basis, under common ownership, and expand its branded apparel business.Β Β 

- A 51% stake in Educas Europe Investments LLP ("a sister partnership to Educas Investments LLP, one of Fund I's portfolio investments), established to acquire independent schools in Europe, which has subsequently acquired Bearwood College and Fulham Prep School.Β 

- A majority stake in Facile.it, Italy's leading price comparison site for motor insurance, energy, telecoms and personal finance.Β 

- In the post reporting period, Damovo II Sarl, a provider of enterprise information communication technology (ICT) services and solutions, which will seek to replicate the success of Daisy Group plc ("Daisy") through a European roll-up strategy led by founder of Daisy, Matthew Riley. Β 

Β· Strong disposals, including,

- Fund I's disposal of its 13.6% shareholding in Daisy, providing a gross money multiple of 36x and an IRR of 71%.

Β 

- In the post reporting period, Fund II, together with its co-owner Bellaxa AG, sold intergenia Holding GmbH and its subsidiaries ("intergenia") to HEG Co. GmbH ("Host Europe"), representing a gross money multiple of 1.5x and IRR of 47% for Fund II in under 12 months.

Β 

Β 

Peter Dubens, Director, commented:

Β 

"I am delighted that the second fund exceeded its target and closed with total commitments of €524 million. To-date 42% of commitments to Fund II have been drawn and have funded an attractive portfolio of investments.

Β 

NAV performance in the period was somewhat attenuated by the weakening of the Euro during the year. Nevertheless significant disposals from both Funds, specifically the exits from Daisy and intergenia both of which delivered good returns, demonstrates Oakley's ability to deliver strong investment returns for our investors. Since inception in 2007, the Funds have returned an aggregate gross money multiple of 2.6x and an IRR of 45%, from realised investments."

Β 

Β 

For further information please contact:

Β 

Oakley Capital Investments Limited

+44 20 7766 6900

Peter Dubens

Β 

FTI Consulting

+44 20 3727 1000

Edward Bridges / Emily Desmier

Β 

Liberum Capital Limited (Nominated Adviser & Broker)

+44 20 3100 2000

Steve Pearce / Tom Fyson

Β 

Β 

About Oakley Capital Investments Limited ("OCIL")

Oakley Capital Investments Limited is a Bermudan based company listed on AIM. OCIL seeks to

provide investors with long term capital appreciation through its investments in Oakley Capital Private Equity L.P. and Oakley Capital Private Equity II and, over time, through co-investment opportunities.

Β 

About Oakley Capital Private Equity L.P. and Oakley Capital Private Equity II

Oakley Capital Private Equity L.P. and its successor fund, Oakley Capital Private Equity II, are both unlisted UK and European mid-market private equity funds with the aim of providing investors with significant long term capital appreciation. The investment strategy of both funds is to focus on buy-out opportunities in industries with the potential for growth, consolidation and performance improvement. Both funds seek to invest in companies with scale in their industry subsectors, thereby creating a sustainable earnings stream which should command a premium on exit.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
TSTSSLFWMFISEDE
Date   Source Headline
27th Jan 20215:06 pmRNSDirector Dealing
27th Jan 20217:00 amRNSTrading update for the year ended 31 December 2020
26th Jan 20217:00 amRNSInvestment in idealista
7th Jan 20217:00 amRNSSale of the DWS division of the Daisy Group
22nd Dec 20204:11 pmRNSHolding(s) in Company
11th Dec 20202:33 pmRNSDirector Declaration
4th Dec 20203:58 pmRNSHolding(s) in Company
3rd Dec 20204:50 pmEQSHardman & Co Research: Oakley Capital Investments (OCI): NAV: conservative, robust and with growth upside
3rd Dec 20201:52 pmRNSTransaction in Own Shares
25th Nov 20207:00 amRNSHolding(s) in Company
23rd Oct 20207:00 amRNSDirector/PDMR Shareholding
22nd Oct 20207:00 amRNSAcquisition of WindStar Medical
6th Oct 202012:42 pmRNSHolding(s) in Company
6th Oct 20207:00 amRNSTransaction in Own Shares (Amendment)
2nd Oct 20204:33 pmRNSTransaction in Own Shares
2nd Oct 20207:00 amRNSShare Buy-Back Programme
1st Oct 20207:00 amRNSAcquisition of 7NXT
30th Sep 20201:54 pmRNSAppointment of Non-Executive Director
17th Sep 20207:00 amRNSOakley sells Casa.it to EQT
10th Sep 20207:00 amRNSResults for the six months ended 30 June 2020
1st Sep 20207:20 amEQSHardman & Co Research: Oakley Capital Investments (OCI) - initiation of coverage: 'When it rains gold, put out the bucket'
4th Aug 20203:09 pmRNSHolding(s) in Company
29th Jul 20206:15 pmRNSTransaction in Own Shares
29th Jul 20207:00 amRNSTrading update for the six months ended 30 June 20
15th Jul 20209:30 amRNSKepler Trust Intelligence: New Research
6th Jul 20207:00 amRNSCapital Commitment
30th Jun 20207:00 amRNSDirectorate Change
24th Jun 20206:02 pmRNSDirector Dealing
22nd Jun 202012:22 pmRNSHolding(s) in Company
19th Jun 20205:38 pmRNSDirector Dealing
19th Jun 20207:01 amRNSDirector Dealing
19th Jun 20207:00 amRNSDirector Dealing
18th Jun 20205:57 pmRNSHolding(s) in Company
18th Jun 20204:42 pmRNSTransaction in Own Shares
18th Jun 20207:00 amRNSShare Buy-Back
1st Jun 20202:25 pmRNSDirector Declaration
27th May 20205:01 pmRNSHolding(s) in Company
27th May 20207:00 amRNSResult of Annual General Meeting
22nd May 20204:33 pmRNSTime Out equity fundraise and OCI loan repayment
19th May 20207:00 amRNSDirector Declaration
7th May 20207:00 amRNSDirectorate Change and Total Voting Rights
1st May 20207:00 amRNSNotice of Annual General Meeting
8th Apr 20207:00 amRNSOakley completes sale of investment in Inspired
25th Mar 20207:00 amRNSCOVID-19 Update
20th Mar 20207:00 amRNSAnnual Report and Accounts 2019
18th Mar 20204:22 pmRNSTransaction in own Shares
18th Mar 20207:00 amRNSShare Buy-Back
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
12th Mar 20207:33 amRNSResults analysis from Kepler Trust Intelligence

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.